Clinical Trials in Colorado

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Status

Study

Lead sponsor

Phase

Enrol

US states

Start

Recruiting

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer

Relay Therapeutics, Inc.

Phase 3

540

Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia

2025-08-26

Recruiting

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

NCT06999187Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer

Dren Bio

Phase 1

Colorado, Florida, North Carolina, Oklahoma, South Carolina, Texas, Virginia

2025-06-03

Active, closed

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

NCT06590857Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer

RayzeBio, Inc.

Phase 1/2

Arizona, California, Colorado, Florida, Georgia, Indiana, Massachusetts, Michigan

2024-07-19

Active, closed

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

NCT05508906Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer

Olema Pharmaceuticals, Inc.

Phase 1

190

Arizona, California, Colorado, Florida, Iowa, Massachusetts, Michigan, Minnesota

2022-08-31

Recruiting

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

NCT05216432PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer

Relay Therapeutics, Inc.

Phase 1

930

Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Massachusetts

2021-12-08

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-usa/state/colorado

Query this register directly

GET /api/trials?country=usa&status=recruiting&format=json Try it now →